8 results on '"Molteni, Alfredo"'
Search Results
2. Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
- Author
-
Pungolino, Ester, D'adda, Mariella, De Canal, Gabriella, Trojani, Alessandra, Perego, Alessandra, Elena, Chiara, Lunghi, Francesca, Turrini, Mauro, Borin, Lorenza, Iurlo, Alessandra, Latargia, Maria Luisa, Carraro, Maria Cristina, Spina, Francesco, Artale, Salvatore, Anghilieri, Michela, Molteni, Alfredo, Caramella, Marianna, Baruzzo, Giacomo, Nichelatti, Michele, and Di Camillo, Barbara
- Subjects
MYELOID leukemia ,BONE marrow cells ,DIAGNOSIS ,JAK-STAT pathway ,CHRONIC myeloid leukemia - Abstract
Chronic Myeloid Leukemia is a clonal disorder characterized by the presence of the Ph‐chromosome and the BCR‐ABL tyrosine‐kinase (TK). Target‐therapy with Imatinib has greatly improved its outcome. Deeper and faster responses are reported with the second‐generation TKI Nilotinib. Sustained responses may enable TKI discontinuation. However, even in a complete molecular response, some patients experience disease recurrence possibly due to persistence of quiescent leukemic CD34+/lin−Ph+ stem cells (LSCs). Degree and mechanisms of LSCs clearance during TKI treatment are not clearly established. The PhilosoPhi34 study was designed to verify the in‐vivo activity and timecourse of first‐line Nilotinib therapy on BM CD34+/lin−Ph+ cells clearance. Eighty‐seven CP‐CML patients were enrolled. BM cells were collected and tested for Ph+ residual cells, at diagnosis, 3, 6 and 12 months of treatment. FISH analysis of unstimulated CD34+/lin− cells in CCyR patients were positive in 8/65 (12.3%), 5/71 (7%), 0/69 (0%) evaluable tests, respectively. Per‐Protocol analysis response rates were as follows: CCyR 95% at 12 months, MR4.5 31% and 46% at 12 and 36 months, respectively. An exploratory Gene Expression Profiling (GEP) study of CD34+/lin− cells was performed on 30 patients at diagnosis and after, on 79 patients at diagnosis vs 12 months of nilotinib treatment vs 10 healthy subjects. Data demonstrated some genes significantly different expressed: NFKBIA, many cell cycle genes, ABC transporters, JAK‐STAT signaling pathway (JAK2). In addition, a correlation between different expression of some genes (JAK2, OLFM4, ICAM1, NFKBIA) among patients at diagnosis and their achievement of an early and deeper MR was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
- Author
-
Fabiani, Emiliano, Calabrese, Chiara, Niscola, Pasquale, Balleari, Enrico, Molteni, Alfredo, Finelli, Carlo, Falconi, Giulia, Fenu, Susanna, Fianchi, Luana, Criscuolo, Marianna, Salvi, Flavia, Lavorgna, Serena, Buccisano, Francesco, Maurillo, Luca, Lo Coco, Francesco, Cilloni, Daniela, and Voso, Maria Teresa
- Subjects
MYELOFIBROSIS ,MYELODYSPLASTIC syndromes ,CHELATION - Abstract
The article focuses on a study which analyzes somatic mutations and haematological response to iron chelation in myelodysplastic syndromes (MDS). Topics being presented include the molecular mechanisms associated with haematological improvement during iron chelating treatment in MDS and the use of oral iron chelator deferasirox according to guidelines in patients with MDS or primary myelofibrosis.
- Published
- 2019
- Full Text
- View/download PDF
4. Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an “Old‐fashioned” Drug be Effective?
- Author
-
Riva, Marta, Bosi, Alessandro, Rizzo, Lorenzo, Mazzon, Federico, Ferrari, Silvia, Lussana, Federico, Borin, Lorenza, Castelli, Andrea, Cairoli, Roberto, Barcellini, Wilma, Molteni, Alfredo, and Fattizzo, Bruno
- Published
- 2023
- Full Text
- View/download PDF
5. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
- Author
-
Molteni, Alfredo, Riva, Marta, Cesana, Clara, Speziale, Valentina, Nichelatti, Michele, Scarpati, Barbara, Greco, Rosa, Ravano, Emanuele, Cairoli, Roberto, Rossini, Silvano, and Morra, Enrica
- Subjects
- *
MYELODYSPLASTIC syndromes , *BONE marrow diseases , *DYSPLASIA , *FLOW cytometry , *PROGNOSIS , *HEMATOLOGY , *MICROSCOPY - Abstract
Objective The medullar blast count is a milestone in the prognostic assessment in myelodysplastic syndromes ( MDS). The optical microscopy ( OM) may sometimes be inaccurate in this disease. The aim of this work is to test the flow immunocytometric ( FCM) determinations of medullar immature cells ( CD45±) and the expression, among them, of CD33, CD34, and CD117 markers, for their prognostic relevance. Methods In a retrospective analysis of 98 patients affected by MDS, the IPSS was re-calculated by means of the FCM determination of blasts. Survival of patients at low or intermediate-1 IPSS risk was compared with the survival of patients at intermediate-2 or high IPSS risk. In the 64 cases with OM blast count lower than 5%, the survival of patients with the FCM count of medullar blasts ≤2% was compared with that of patients with FCM count >2%. Results Each single marker had a prognostic weight comparable to the optical blast count. The FCM blast count was particularly efficient in distinguishing the risk of having up to 2% or more than 2% of blasts in patients without OM excess of blasts. Conclusion This method is interesting as prognostic tool, especially in patients without excess of blast. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond ( GIMEMA MDS0306 Trial).
- Author
-
Angelucci, Emanuele, Santini, Valeria, Tucci, Anna Angela, Quaresmini, Giulia, Finelli, Carlo, Volpe, Antonio, Quarta, Giovanni, Rivellini, Flavia, Sanpaolo, Grazia, Cilloni, Daniela, Salvi, Flavia, Caocci, Giovanni, Molteni, Alfredo, Vallisa, Daniele, Voso, Maria Teresa, Fenu, Susanna, Borin, Lorenza, Latte, Giancarlo, Alimena, Giuliana, and Storti, Sergio
- Subjects
DEFERASIROX ,BLOOD transfusion ,MYELODYSPLASTIC syndromes ,DRUG efficacy ,CHELATION therapy ,IRON in the body ,CLINICAL trials - Abstract
Background In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes ( MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted. Methods The safety and efficacy of deferasirox was examined in a prospective, open-label, single-arm, multicenter trial of transfusion-dependent patients with International Prognostic Scoring System low- or intermediate-1-risk MDS and evidence of transfusion-related iron overload. The effects of deferasirox therapy on hematological response and disease progression were also examined. Results Of 159 participants enrolled from 37 Italian centers, 152 received ≥1 dose of deferasirox (initiated at 10-20 mg/kg/day and titrated as appropriate), and 68 completed the study. Of 84 patients who discontinued deferasirox therapy, 22 died during the trial, and 28 withdrew due to an adverse event ( AE). Fourteen treatment-related grade 3 AEs occurred in 11 patients, whereas no grade 4 or 5 drug-related AEs were reported. Significant risks for dropout were a higher serum ferritin level at baseline, a higher MDS-Specific Comorbidity Index, and a shorter diagnosis-enrollment interval. Median serum ferritin level fell from 1966 ng/mL to 1475 ng/mL ( P < 0.0001). The cumulative incidence of transfusion independence, adjusted for death and disease progression, was 2.6%, 12.3%, and 15.5% after 6, 9, and 12 months, respectively. Conclusions Deferasirox therapy in transfusion-dependent patients with MDS was moderately well tolerated and effectively lowered serum ferritin levels. Positive hematological responses were observed, and a subset of patients achieved transfusion independence. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
- Author
-
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, and Della Porta MG
- Subjects
- Humans, Activin Receptors, Type II, Immunoglobulin Fc Fragments, Myelodysplastic Syndromes drug therapy, Anemia, Sideroblastic drug therapy
- Published
- 2023
- Full Text
- View/download PDF
8. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
- Author
-
Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli M, Basilico C, Galeone C, Pelucchi C, and Rossi G
- Subjects
- Aged, Aged, 80 and over, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic therapeutic use, Cause of Death, Decitabine adverse effects, Disease Progression, Female, Humans, Infections etiology, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute mortality, Male, Multicenter Studies as Topic statistics & numerical data, Observational Studies as Topic statistics & numerical data, Prognosis, Proportional Hazards Models, Risk Factors, Treatment Outcome, Decitabine therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
Despite widespread use of decitabine to treat acute myeloid leukaemia (AML), data on its effectiveness and safety in the real-world setting are scanty. Thus, to analyze the performance of decitabine in clinical practice, we pooled together patient-level data of three multicentric observational studies conducted since 2013 throughout Italy, including 306 elderly AML patients (median age 75 years), unfit for intensive chemotherapy, treated with first-line decitabine therapy at the registered schedule of 20 mg/m
2 /iv daily for 5 days every 4 weeks. Overall response rate (ORR), overall survival (OS) curves, and multivariate hazard ratios (HRs) of all-cause mortality were computed. Overall, 1940 cycles of therapy were administered (median, 5 cycles/patient). A total of 148 subjects were responders and, therefore, ORR was 48.4%. Seventy-one patients (23.2%) had complete remission, 32 (10.5%) had partial remission, and 45 (14.7%) had haematologic improvement. Median OS was 11.6 months for patients with favourable-intermediate cytogenetic risk and 7.9 months for those with adverse cytogenetic risk. Median relapse-free survival after CR was 10.9 months (95% confidence interval [CI]: 8.7-16.0). In multivariate analysis, mortality was higher in patients with adverse cytogenetic risk (HR=1.58; 95% CI: 1.13-2.21) and increased continuously with white blood cell (WBC) count (HR=1.12; 95% CI: 1.06-1.18). A total of 183 infectious adverse events occurred in 136 patients mainly (>90%) within the first five cycles of therapy. This pooled analysis of clinical care studies confirmed, outside of clinical trials, the effectiveness of decitabine as first-line therapy for AML in elderly patients unfit for intensive chemotherapy. An adverse cytogenetic profile and a higher WBC count at diagnosis were, in this real life setting, unfavourable predictors of survival., (© 2019 John Wiley & Sons, Ltd.)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.